


# NEWSRELEASE

DELMEDICA INVESTMENTS February 28th 2007



Clinical trials supporting the impressive results of DMI's Dunev Thermometer are ongoing with at least 5 trials due for completion in 2007.



## ON THE MOVE

**As Delmedica Investments Limited ('DMI') continues to develop important technologies and attract revolutionary medical advancements, we are pleased to announce the opening of another office in Asia. Strategically located in Singapore, the new head office is perfectly situated to capitalise on significant grants that will further contribute to the company's core development objectives.**

**DMI Singapore:** 7 Temasek Boulevard, #06-01, Suntec Tower 1, Singapore 038987.  
Tel: (+65) 6415 3102, Fax: (+65) 6415 3108

## Clinical Trials to be completed in 2007

Clinical trials supporting the impressive clinical findings of DMI's Dunev Thermometer are ongoing with at least 5 trials due for completion in 2007. Once available, results will be published as Abstracts and Clinical Papers will then be submitted to International Journals.

Meanwhile, DMI has recently submitted a compelling clinical paper to the 'International Journal of Respiratory Medicine'. Once published, the paper will be made available for review at [www.delmedicainvestments.com](http://www.delmedicainvestments.com)

## Dunev Prepares for Commercialisation

DMI will soon announce the appointment of an experienced and highly respected Non-Executive Director. This appointment is an important investment in expediting the successful commercialisation of the Dunev Thermometer along with other key DMI 'ready-to-market' technologies.

## US Venue for Ongoing MUCOAD™ negotiations

**The Fortune Apex Development ('Fortune Apex') Scientific Advisory Board ('SAB') continues to liaise with the Fortune Apex board on important discussions with US pharmaceutical corporations progressing evaluation and Licensing Agreements.**

All aspects of MUCOAD™'s imminent commercialisation are being coordinated by the "Strategic Pharmaceutical Company" - a Joint Venture company formed with Strategic Pharmaceutical Advisors ('SrxA') - a leading US pharmaceutical marketing organisation with an impressive history of successful new product introductions to the target pharmaceutical companies.

**SrxA expect initial Evaluation agreements will be signed by early April 2007.**

## Annual Asthma/Allergy/Immunology Summit

**The most prominent physicians in allergy, asthma and immunology will gather in San Diego for the 2007 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI). This year's meeting will bring together more than 7,000 allergists/immunologists, allied health professionals and researchers from around the world to discuss all aspects of the specialty.**

Key DMI personnel and the Directors of Fortune Apex will join SrxA in attending the seminar in San Diego (22nd-25th Feb '07). With a targeted audience of the world's leading specialists and practitioners, the seminar represents an ideal platform from which to promote DMI's 'ready-to-market' technologies.

For further information, please review the conference web site:

[http://www.aaaai.org/members/annual\\_meeting/am2007/](http://www.aaaai.org/members/annual_meeting/am2007/)

[www.delmedicainvestments.com](http://www.delmedicainvestments.com)

**DELMEDICA**

Delmedica Investments Ltd • 7 Temasek Boulevard • #06-01 • Suntec Tower 1 • Singapore 038987